Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention

被引:0
|
作者
Afshar, Majid [1 ]
Linck, Emma J. Graham [1 ]
Spicer, Alexandra B. [1 ]
Rotrosen, John [2 ]
Salisbury-Afshar, Elizabeth M. [1 ]
Sinha, Pratik [3 ]
Semler, Matthew W. [4 ]
Churpek, Matthew M. [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, 1685 Highland Ave, Madison, WI 53705 USA
[2] NYU, Grossman Sch Med, New York, NY USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
关键词
opioid use disorder; opioid treatment; heterogeneity of treatment effect; buprenorphine; naltrexone; EXTENDED-RELEASE NALTREXONE; RATING-SCALES; METHADONE; XBOT;
D O I
10.1097/ADM.0000000000001313
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objective: A trial comparing extended-release naltrexone and sublingual buprenorphine-naloxone demonstrated higher relapse rates in individuals randomized to extended-release naltrexone. The effectiveness of treatment might vary based on patient characteristics. We hypothesized that causal machine learning would identify individualized treatment effects for each medication. Methods: This is a secondary analysis of a multicenter randomized trial that compared the effectiveness of extended-release naltrexone versus buprenorphine-naloxone for preventing relapse of opioid misuse. Three machine learning models were derived using all trial participants with 50% randomly selected for training (n = 285) and the remaining 50% for validation. Individualized treatment effect was measured by the Qini value and c-for-benefit, with the absence of relapse denoting treatment success. Patients were grouped into quartiles by predicted individualized treatment effect to examine differences in characteristics and the observed treatment effects. Results: The best-performing model had a Qini value of 4.45 (95% confidence interval, 1.02-7.83) and a c-for-benefit of 0.63 (95% confidence interval, 0.53-0.68). The quartile most likely to benefit from buprenorphine-naloxone had a 35% absolute benefit from this treatment, and at study entry, they had a high median opioid withdrawal score (P < 0.001), used cocaine on more days over the prior 30 days than other quartiles (P < 0.001), and had highest proportions with alcohol and cocaine use disorder (P <= 0.02). Quartile 4 individuals were predicted to be most likely to benefit from extended-release naltrexone, with the greatest proportion having heroin drug preference (P = 0.02) and all experiencing homelessness (P < 0.001). Conclusions: Causal machine learning identified differing individualized treatment effects between medications based on characteristics associated with preventing relapse.
引用
收藏
页码:511 / 519
页数:9
相关论文
共 50 条
  • [1] Optimizing opioid use disorder treatment with naltrexone or buprenorphine
    Rudolph, Kara E.
    Diaz, Ivan
    Luo, Sean X.
    Rotrosen, John
    Nunes, Edward, V
    DRUG AND ALCOHOL DEPENDENCE, 2021, 228
  • [2] Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women
    Tran, Tran H.
    Griffin, Brooke L.
    Stone, Rebecca H.
    Vest, Kathleen M.
    Todd, Timothy J.
    PHARMACOTHERAPY, 2017, 37 (07): : 824 - 839
  • [3] Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder
    Randall-Kosich, Olivia
    Andraka-Christou, Barbara
    Totaram, Rachel
    Alamo, Jessica
    Nadig, Mayur
    JOURNAL OF ADDICTION MEDICINE, 2020, 14 (04) : E44 - E52
  • [4] Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone
    Nunes, Edward V.
    Gordon, Michael
    Friedmann, Peter D.
    Fishman, Marc J.
    Lee, Joshua D.
    Chen, Donna T.
    Hu, Mei Chen
    Boney, Tamara Y.
    Wilson, Donna
    O'Brien, Charles P.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 85 : 49 - 55
  • [5] Comparing Two Databases to Identify Access to Buprenorphine Treatment for Opioid Use Disorder
    Anyanwu, Precious
    Varisco, Tyler J.
    Wanat, Matthew A.
    Bapat, Shweta
    Claborn, Kasey
    Thornton, J. Douglas
    JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2022, 36 (02) : 103 - 111
  • [6] Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects
    Wachman, Elisha M.
    Saia, Kelley
    Miller, Melissa
    Valle, Eduardo
    Shrestha, Hira
    Carter, Ginny
    Werler, Martha
    Jones, Hendree
    CLINICAL THERAPEUTICS, 2019, 41 (09) : 1681 - 1689
  • [7] Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder
    Rudolph, Kara E.
    Williams, Nicholas T.
    Goodwin, Alicia T. Singham
    Shulman, Matisyahu
    Fishman, Marc
    Diaz, Ivan
    Luo, Sean
    Rotrosen, John
    Nunes, Edward, V
    DRUG AND ALCOHOL DEPENDENCE, 2022, 239
  • [8] A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol
    Bassiony, Medhat M.
    Abdelfattah, Nelly R.
    Elshabrawy, Amany
    Adly, Mary M.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2024, 39 (06) : 341 - 349
  • [9] Comparing telemedicine to in-person buprenorphine treatment in US veterans with opioid use disorder
    Lin, Lewei A.
    Fortney, John C.
    Bohnert, Amy S. B.
    Coughlin, Lara N.
    Zhang, Lan
    Piette, John D.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 133
  • [10] Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse
    Rudolph, Kara E.
    Shulman, Matisyahu
    Fishman, Marc
    Diaz, Ivan
    Rotrosen, John
    Nunes, Edward, V
    ADDICTION, 2022, 117 (03) : 637 - 645